Loading...
Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
PURPOSE: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections. METHODS: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness aft...
Na minha lista:
| Udgivet i: | Clin Ophthalmol |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8286127/ https://ncbi.nlm.nih.gov/pubmed/34285463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S316271 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|